| 49.11 -1.35 (-2.68%) | 05-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 69.87 |
1-year : | 78.11 |
| Resists | First : | 59.82 |
Second : | 66.87 |
| Pivot price | 54.58 |
|||
| Supports | First : | 48.4 |
Second : | 40.27 |
| MAs | MA(5) : | 54.42 |
MA(20) : | 55.08 |
| MA(100) : | 71.29 |
MA(250) : | 89.11 |
|
| MACD | MACD : | -2.2 |
Signal : | -2.1 |
| %K %D | K(14,3) : | 32.4 |
D(3) : | 58.9 |
| RSI | RSI(14): 29.7 |
|||
| 52-week | High : | 109.5 | Low : | 48.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BSX ] has closed below the lower bollinger band by 3.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BSX ] is to continue within current trading range. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 53.2 - 53.56 | 53.56 - 53.85 |
| Low: | 49.38 - 49.72 | 49.72 - 50 |
| Close: | 49.97 - 50.51 | 50.51 - 50.97 |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Thu, 28 May 2026
This Boston Scientific Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday - Benzinga
Wed, 27 May 2026
Why Did BSX, LI, BJ Stocks Hit 52-Week Lows Today? - Yahoo Finance
Wed, 27 May 2026
Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial - Yahoo Finance
Wed, 27 May 2026
Boston Scientific (BSX) Plunges 10.3% to $51.69 - AlphaStreet
Wed, 27 May 2026
Boston Scientific shares fall 10% on Watchman weakness, competitive pressures - Investing.com
Wed, 27 May 2026
Boston Scientific (BSX) slides after management cuts 2026 growth outlook - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1,490 (M) |
| Shares Float | 1,480 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 95 (%) |
| Shares Short | 28,640 (K) |
| Shares Short P.Month | 23,530 (K) |
| EPS | 2.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.39 |
| Profit Margin | 17.2 % |
| Operating Margin | 20.6 % |
| Return on Assets (ttm) | 6 % |
| Return on Equity (ttm) | 14.6 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 9.53 |
| Sales Per Share | 13.83 |
| EBITDA (p.s.) | 3.69 |
| Qtrly Earnings Growth | 100 % |
| Operating Cash Flow | 4,340 (M) |
| Levered Free Cash Flow | 2,810 (M) |
| PE Ratio | 20.54 |
| PEG Ratio | 0.6 |
| Price to Book value | 2.82 |
| Price to Sales | 3.55 |
| Price to Cash Flow | 16.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|